The Antibody Shared Resource provides a central site for the production of monoclonal and polyclonal antibodies by CSHL Cancer Center personnel. The purpose of this Shared Resource is to provide the resources and expertise to generate these valuable reagents in a highly efficient and cost-effective manner. In the ease of monoclonal antibodies, CSHL Cancer Center scientists provide specific antigens, and the Shared Resource personnel handle all stages of immunization, fusion, primary screening of hybridomas, cell culture, single-cell cloning, freezing and storage of hybridoma lines, and large-scale production of monoclonal antibodies in cell culture or in vivo. Immunization, test bleeds, and production of ascites fluids are coordinated with the personnel of the Animal Shared Resource. Specialized monoclonal antibody screens are closely coordinated with individual scientists. Polyclonal antibody production is outsourced, but the Shared Resource personnel are in charge of processing and distribution of samples, thus reducing the costs and maximizing efficiency. The Shared Resource also tests and implements new techniques, reagents, and assay improvements related to the different stages of antibody production.
The Antibody Shared Resource provides essential services, promotes valuable scientific and technical interactions, and stimulates cancer research that is heavily dependent on high-quality antibody reagents. These reagents help advance basic knowledge about cancer, as well as therapeutics development, and in some cases they also serve to detect and quantitate useful cancer biomarkers.
|Stacchiotti, Silvia; Mir, Olivier; Le Cesne, Axel et al. (2018) Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. Oncologist 23:62-70|
|Banito, Ana; Li, Xiang; Laporte, Aimée N et al. (2018) The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma. Cancer Cell 33:527-541.e8|
|Goncalves, Marcus D; Hwang, Seo-Kyoung; Pauli, Chantal et al. (2018) Fenofibrate prevents skeletal muscle loss in mice with lung cancer. Proc Natl Acad Sci U S A 115:E743-E752|
|Hwang, Dong-Woo; Jaganathan, Anbalagan; Shrestha, Padmina et al. (2018) Chromatin-mediated translational control is essential for neural cell fate specification. Life Sci Alliance 1:e201700016|
|Knott, Simon R V; Wagenblast, Elvin; Khan, Showkhin et al. (2018) Asparagine bioavailability governs metastasis in a model of breast cancer. Nature 554:378-381|
|Biffi, Giulia; Oni, Tobiloba E; Spielman, Benjamin et al. (2018) IL-1-induced JAK/STAT signaling is antagonized by TGF-beta to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov :|
|Xie, Yuanyuan; Cao, Zhen; Wong, Elissa Wp et al. (2018) COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors. J Clin Invest 128:1442-1457|
|Aznarez, Isabel; Nomakuchi, Tomoki T; Tetenbaum-Novatt, Jaclyn et al. (2018) Mechanism of Nonsense-Mediated mRNA Decay Stimulation by Splicing Factor SRSF1. Cell Rep 23:2186-2198|
|Fang, Han; Huang, Yi-Fei; Radhakrishnan, Aditya et al. (2018) Scikit-ribo Enables Accurate Estimation and Robust Modeling of Translation Dynamics at Codon Resolution. Cell Syst 6:180-191.e4|
|Lin, Kuan-Ting; Ma, Wai Kit; Scharner, Juergen et al. (2018) A human-specific switch of alternatively spliced AFMID isoforms contributes to TP53 mutations and tumor recurrence in hepatocellular carcinoma. Genome Res :|
Showing the most recent 10 out of 380 publications